Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer

SIMPLE SUMMARY: Two to three percent of breast cancer patients harbor germline mutation of either BRCA1 or BRCA2 genes. Their tumor cells are deficient in homologous recombination, a BRCA-dependent DNA repair machinery. These deficient cells survive thanks to the PARP-mediated alternative pathway. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Franchet, Camille, Hoffmann, Jean-Sébastien, Dalenc, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392832/
https://www.ncbi.nlm.nih.gov/pubmed/34439286
http://dx.doi.org/10.3390/cancers13164132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392832/
https://www.ncbi.nlm.nih.gov/pubmed/34439286
http://dx.doi.org/10.3390/cancers13164132

Ejemplares similares